Views & Analysis | Perspectives on pharma industry issues

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Market Access

Sponsored

The pre-commercial case for connecting data before acquiring...

For EBPs, launch requires a data strategy that starts with agreement on the KPIs, and those depend on the therapeutic areas.

Articles

This month’s exploration into a pharmaceutical company’s history is the turn of French company Sanofi, which began over 100 years ago as a number of small companies. Sanofi is one of the largest pharmaceutical companies in the world, with a rich history of innovation that…

Articles

Patient registries and why they are essential for rare disea...

How essential are patient registries for rare diseases? Eileen O’Brien discusses, in the third article out of a five-part series from Siren Interactive. At a very basic level a registry is a systematic collection of standardized data on a group of patients. “There are different…

Articles

What’s the most important question in medicine?

PatientsLikeMe founder Ben Heywood discusses the rise in online patient communities and the impact this has had on the awareness of rare diseases. I’m inspired daily by patient stories. They connect with others who have the same disease, often for...

Sales & Marketing

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital